Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, Randomized, Open-label Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of M6620 in Combination With Avelumab and Carboplatin in Comparison to Standard of Care Therapy in Participants With PARPi-resistant Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Trial Profile

A Phase II, Randomized, Open-label Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of M6620 in Combination With Avelumab and Carboplatin in Comparison to Standard of Care Therapy in Participants With PARPi-resistant Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Recruiting
Phase of Trial: Phase II

Latest Information Update: 24 Jan 2019

At a glance

  • Drugs Avelumab (Primary) ; Carboplatin (Primary) ; M 6620 (Primary) ; Bevacizumab; Gemcitabine; Paclitaxel
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors EMD Serono Research & Development Institute
  • Most Recent Events

    • 18 Dec 2018 Status changed from not yet recruiting to recruiting.
    • 14 Nov 2018 Planned initiation date changed from 2 Nov 2018 to 3 Dec 2018.
    • 12 Nov 2018 New source identified and integrated (European Clinical Trials Database record; EudraCT2018-001534-17).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top